Evidence map›Paper›PMID 31985750›Full record

ArticleJAMA internal medicine2020

Post-Acute Kidney Injury Proteinuria and Subsequent Kidney Disease Progression: The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Study.

Chi-Yuan Hsu, Vernon M Chinchilli, Steven Coca, Prasad Devarajan, Nasrollah Ghahramani, Alan S Go, Raymond K Hsu, T Alp Ikizler, James Kaufman, Kathleen D Liu and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in JAMA internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 3 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 3 syntheses or guidelines pooled it, 166 citations in OpenAlex.

  1. Long-term risks of adverse kidney outcomes after acute kidney injury: a systematic review and meta-analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Pooled it
  2. Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024
    Pooled it
  3. Guideline
  4. Plasma Biomarkers of Kidney Tubule Health during Ambulatory AKI and Kidney Function Recovery in SPRINT.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Trial
  5. Associations of Urine Biomarkers During Ambulatory Acute Kidney Injury With Subsequent Recovery in Kidney Function: Findings From the SPRINT Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025
    Trial
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 2 countries.

Chi-Yuan HsuDivision of Nephrology, University of California School of Medicine, San Francisco, San Francisco.
Vernon M ChinchilliDepartment of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey.
Steven CocaDivision of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York.
Prasad DevarajanCincinnati Children's Hospital, Division of Nephrology and Hypertension, University of Cincinnati, Cincinnati, Ohio.
Nasrollah GhahramaniDivision of Nephrology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey.
Alan S GoDivision of Nephrology, University of California School of Medicine, San Francisco, San Francisco.
Raymond K HsuDivision of Nephrology, University of California School of Medicine, San Francisco, San Francisco.
T Alp IkizlerVanderbilt Center for Kidney Disease, Division of Nephrology & Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee.
James KaufmanRenal Section, Veterans Affairs New York Harbor Health Care System, New York University School of Medicine, New York.
Kathleen D LiuDivision of Nephrology, University of California School of Medicine, San Francisco, San Francisco.
Chirag R ParikhDivision of Nephrology, Johns Hopkins School of Medicine, Baltimore, Maryland.
W Brian ReevesUniversity of Texas, Long School of Medicine, San Antonio.
Mark WurfelDivision of Pulmonary and Critical Care Medicine, University of Washington, Seattle.
Michael ZappitelliHospital for Sick Children, Division of Nephrology, Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
Paul L KimmelDivision of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Edward D SiewVanderbilt Center for Kidney Disease, Division of Nephrology & Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee.
ASSESS-AKI Investigators
University of California, San Francisco · USPennsylvania State University · USVanderbilt University Medical Center · USIcahn School of Medicine at Mount Sinai · USJohns Hopkins University · USNational Institutes of Health · USNew York University · USSickKids Foundation · CAThe University of Texas at San Antonio · USUniversity of Cincinnati · USUniversity of Washington · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Data Coordinating Center for the Natural History of AKI ConsortiumU01DK082183 · NIDDK · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI CHINCHILLI, VERNON M · 2008 to 2018
$9.7M
Proteomics CoreP50DK096418 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI DEVARAJAN, PRASAD · 2012 to 2021
$8.4M
Progression of Acute Kidney Injury to Chronic Kidney DiseaseU01DK082185 · NIDDK · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2008 to 2017
$5.1M
Impact of Acute Kidney Injury on Kidney Disease ProgressionU01DK082192 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI IKIZLER, TALAT ALP · 2008 to 2018
$5.0M
Prospective Evaluation of Acute Kidney Injury (PEAK) CohotU01DK082223 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI GO, ALAN S · 2008 to 2018
$4.0M
Acute kidney injury among patients with chronic kidney diseaseR01DK114014 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN · 2018 to 2021
$3.0M
Identifying opportunities to lower rates of AKI and improve outcomesR01DK101507 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GO, ALAN S, HSU, CHI-YUAN · 2014 to 2017
$2.1M
Acute Kidney Injury: A Novel Risk Factor for Cardiovascular EventsR01DK098233 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIU, KATHLEEN D · 2014 to 2017
$1.9M
Enhancing appreciation of the clinical significance of acute kidney injuryK23DK100468 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, RAYMOND · 2013 to 2017
$892k
Clinical Outcomes after Dialysis-Requiring Acute Kidney InjuryR03DK111881 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, RAYMOND · 2017 to 2018
$159k
NCATS NIH HHS UL1 TR001863NIDDK NIH HHS K23 DK100468NIDDK NIH HHS P50 DK096418NIDDK NIH HHS R01 DK098233NIDDK NIH HHS R01 DK101507NIDDK NIH HHS R01 DK114014NIDDK NIH HHS R03 DK111881NIDDK NIH HHS U01 DK082183NIDDK NIH HHS U01 DK082185NIDDK NIH HHS U01 DK082192NIDDK NIH HHS U01 DK082223
6 · The paper itself

Abstract

Importance: Among patients who had acute kidney injury (AKI) during hospitalization, there is a need to improve risk prediction such that those at highest risk for subsequent loss of kidney function are identified for appropriate follow-up. Objective: To evaluate the association of post-AKI proteinuria with increased risk of future loss of renal function. Design, Setting, and Participants: The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Study was a multicenter prospective cohort study including 4 clinical centers in North America included 1538 patients enrolled 3 months after hospital discharge between December 2009 and February 2015. Exposures: Urine albumin-to-creatinine ratio (ACR) quantified 3 months after hospital discharge. Main Outcomes and Measures: Kidney disease progression defined as halving of estimated glomerular filtration rate (eGFR) or end-stage renal disease. Results: Of the 1538 participants, 769 (50%) had AKI durring hospitalization. The baseline study visit took place at a mean (SD) 91 (23) days after discharge. The mean (SD) age was 65 (13) years; the median eGFR was 68 mL/min/1.73 m2; and the median urine ACR was 15 mg/g. Overall, 547 (37%) study participants were women and 195 (13%) were black. After a median follow-up of 4.7 years, 138 (9%) participants had kidney disease progression. Higher post-AKI urine ACR level was associated with increased risk of kidney disease progression (hazard ratio [HR], 1.53 for each doubling; 95% CI, 1.45-1.62), and urine ACR measurement was a strong discriminator for future kidney disease progression (C statistic, 0.82). The performance of urine ACR was stronger in patients who had had AKI than in those who had not (C statistic, 0.70). A comprehensive model of clinical risk factors (eGFR, blood pressure, and demographics) including ACR provided better discrimination for predicting kidney disease progression after hospital discharge among those who had had AKI (C statistic, 0.85) vs those who had not (C statistic, 0.76). In the entire matched cohort, after taking into account urine ACR, eGFR, demographics, and traditional chronic kidney risk factors determined 3 months after discharge, AKI (HR, 1.46; 95% CI, 0.51-4.13 for AKI vs non-AKI) or severity of AKI (HR, 1.54; 95% CI, 0.50-4.72 for AKI stage 1 vs non-AKI; HR, 0.56; 95% CI, 0.07-4.84 for AKI stage 2 vs non-AKI; HR, 2.24; 95% CI, 0.33-15.29 for AKI stage 3 vs non-AKI) was not independently associated with more rapid kidney disease progression. Conclusions and Relevance: Proteinuria level is a valuable risk-stratification tool in the post-AKI period. These results suggest there should be more widespread and routine quantification of proteinuria after hospitalized AKI.

Indexed as

Acute Kidney InjuryAgedBlood PressureDisease ProgressionFemaleGlomerular Filtration RateHumansKidney Failure, ChronicMaleMiddle AgedProspective StudiesProteinuria

Identifiers

PMID31985750
PMCPMC6990681
OpenAlexW3000897988

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.